Syros Pharmaceuticals Shares Plummet Premarket After Study Failure
Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.
Syros Stock - Investors of Syros Pharmaceuticals Encouraged to Contact Kehoe Law Firm, P.C. - SYRS
Philadelphia, Pennsylvania-- (Newsfile Corp. - November 13, 2024) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or ...
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...
Morningstar8d
Syros Pharmaceuticals Inc SYRS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
precisionmedicineonline2d
Syros Pharmaceuticals' Phase III Trial of Tamibarotene in MDS Fails to Meet Primary Endpoint
NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...
Benzinga.com2d
Syros Pharmaceuticals (NASDAQ:SYRS) Stock, Short Interest Report
Short interest in Syros Pharmaceuticals Inc (NASDAQ:SYRS) decreased during the last reporting period, falling from 999.93K to 952.60K. This put 3.87% of the company's publicly available shares ...
Investing2d
Syros Pharmaceuticals' SWOT analysis: stock faces headwinds after trial setback
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company focused on developing treatments for cancer and blood disorders, has encountered significant challenges in its clinical ...